Obesity-hypoventilation in Metabolic Syndrom Patients
Prevalence of Obesity-hypoventilation Syndrome in Patients With Metabolic Syndrome.
Study Overview
Status
Status
Conditions
Conditions
Detailed Description
After being informed about the study and potential risks, patient agreed to participate and undergo :
a functional respiratory exploration, an arterial blood gas analyze, and a polygraphy coupled with a capnography during the same night.
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Contacts and Locations
Study Contact
Study Contact
- Name: Delphine Delample, PhD
- Phone Number: +33 0612155648
- Email: d.delample@sosoxygene.com
Study Locations
-
-
-
Bondigoux, France, 31340
- Recruiting
- Clinique du Château de Vernhes
-
Contact:
- Mathieu Despeaux, MD
- Phone Number: +33 0561372727
- Email: m.despeaux@cliniquevernhes.fr
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
- BMI>30 kg/m2
- no treatment with CPAP nor NIV
Exclusion Criteria:
- obstructive respiratory disease
- non-treated cardiac dysfunction
Study Plan
How is the study designed?
Design Details
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Capnia
Time Frame: Up to one mont after inclusion
|
Arterial pression in CO2 and transcutaneous pression in CO2
|
Up to one mont after inclusion
|
|
Arterial pression in CO2
Time Frame: At the inclusion
|
PaCO2
|
At the inclusion
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
BMI
Time Frame: At the inclusion
|
body mass index
|
At the inclusion
|
|
Arterial pression in oxygen
Time Frame: At the inclusion
|
PaO2
|
At the inclusion
|
|
Arterial blood bicarbonates
Time Frame: At the inclusion
|
HCO3-
|
At the inclusion
|
|
Arterial blood gases
Time Frame: At the inclusion
|
pH
|
At the inclusion
|
|
Hemoglobin
Time Frame: At the inclusion
|
Hb
|
At the inclusion
|
|
obstructive sleep apnea items
Time Frame: Up to one mont after inclusion
|
Apnea-hypopnea index
|
Up to one mont after inclusion
|
|
Night Oxygen saturation
Time Frame: Up to one mont after inclusion
|
SpO2
|
Up to one mont after inclusion
|
|
somnolence
Time Frame: At the inclusion
|
EPWORTH questionnaire; Minimum = 0; Maximum = 24, Higher score means a worth outcome
|
At the inclusion
|
|
Physical activity level
Time Frame: At the inclusion
|
Ricci&Gagnon questionnaire, Minimum = 9; Maximum = 45, Higher score means a worth outcome
|
At the inclusion
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Mathieu Despeaux, MD, Clinique du Château de Vernhes
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Pathologic Processes
- Glucose Metabolism Disorders
- Metabolic Diseases
- Nervous System Diseases
- Respiratory Tract Diseases
- Apnea
- Respiration Disorders
- Sleep Disorders, Intrinsic
- Dyssomnias
- Sleep Wake Disorders
- Disease
- Overnutrition
- Nutrition Disorders
- Overweight
- Body Weight
- Signs and Symptoms, Respiratory
- Insulin Resistance
- Hyperinsulinism
- Sleep Apnea Syndromes
- Respiratory Insufficiency
- Sleep Apnea, Obstructive
- Syndrome
- Obesity
- Metabolic Syndrome
- Hypoventilation
- Obesity Hypoventilation Syndrome
Other Study ID Numbers
Other Study ID Numbers
- 2019-A02866-51
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.